THIS WEEK'S FEATURE
Closely-held Rgenix has identified novel cancer targets regulated by microRNA pathways, which are key drivers of cancer progression, and developed first-in-class treatments that have the potential to modulate these targets.
Closely-held Lobo Genetics is readying the initial launch in the current quarter of 2018 of its Lobo Cube DNA testing device to bring the science of cannabis genetics to doctors and consumers.
CHF Solutions (NASDAQ:CHFS) has expanded its U.S. commercial team to 13 sales territories for its Aquadex FlexFlow system, an ultrafiltration treatment for patients with fluid overload who have failed diuretic therapy, along with expanded distribution in Europe and Asia.
With FDA approval in hand for its gammaCore Sapphire therapy for the acute treatment of episodic cluster headaches and migraines, electroCore (NASDAQ:ECOR) is now focused on commercialization and reimbursement efforts in the U.S.
Closely-held elminda’s Brain Networks Analytics (BNA) technology is going beyond genetics, imaging and behavioral tests to unlock brain functioning and how the brain changes over time, combining Big Data and AI-driven analytics in a single technology platform.